Tyclav 1.2 IV Injection — Co-Amoxiclav 1.2g (Amoxicillin 1g + Clavulanate 200mg) by Beximco

Tyclav 1.2 IV Injection — Co-Amoxiclav 1.2g (Amoxicillin 1g + Clavulanate 200mg) | Beximco Pharmaceuticals

Overview

Tyclav 1.2 IV is Beximco's high-dose intravenous co-amoxiclav injection — Amoxicillin Sodium 1000mg + Potassium Clavulanate 200mg per vial. This is the standard IV co-amoxiclav dose for most severe hospital infections, providing double the amoxicillin and clavulanate of the 0.6g vial. Tyclav 1.2 IV is the preferred formulation for serious infections requiring maximum beta-lactamase-protected coverage and for surgical prophylaxis. It can be used as a single large-vial dose or as the standard TDS/QDS regimen for severe infections. IV therapy is typically followed by step-down to oral co-amoxiclav when clinical stability is achieved.

Tyclav IV Range Comparison

Indications

• Severe Community-Acquired Pneumonia — requiring hospitalisation and IV therapy
• Hospital-Acquired Pneumonia (non-Pseudomonal, early onset)
• Severe Intra-abdominal Infections — peritonitis, complicated appendicitis, cholangitis
• Severe Pelvic Infections — salpingitis, tubo-ovarian abscess, post-caesarean endometritis
• Septicaemia / Bacteraemia — from susceptible organisms (not suspected Pseudomonas, MRSA)
• Severe Skin & Soft Tissue Infections — necrotising fasciitis (as part of combination), Fournier's gangrene, severe cellulitis
• Diabetic Foot Infections (moderate-severe with systemic signs) — initial IV coverage
• Bone & Joint Infections — osteomyelitis, septic arthritis (IV phase)
• Surgical Prophylaxis — GI, biliary, cardiac, orthopaedic, gynaecological procedures (single dose)
• Endocarditis Treatment — susceptible Streptococci, Enterococci (often in combination)

Dosage & Administration

Reconstitution: Add 20mL Water for Injections for IV bolus (give over 3–4 minutes), or dilute in 100mL Sodium Chloride 0.9% for infusion (give over 30 minutes). Do not exceed 30 minutes per infusion. Use immediately after reconstitution. Do not mix with aminoglycosides, blood products, or protein solutions in the same line.

Special Note for Diabetic Patients

Tyclav 1.2 IV is critical for moderate-to-severe diabetic foot infections (DFI) — particularly those with systemic signs (fever, elevated WBC, systemic sepsis) or deep tissue involvement. The IDSA DFI guidelines support IV co-amoxiclav for moderate-severe DFI requiring hospitalisation. Key clinical scenario: DFI with osteomyelitis (IV phase 4–6 weeks, then step-down to oral); post-debridement wound cover; peri-operative prophylaxis for DFI surgical procedures. No glucose effects. Compatible with all diabetes medications. Monitor electrolytes carefully in diabetics with renal impairment (both sodium and potassium in formulation).

Drug Interactions

Side Effects

• IV Site: Phlebitis, thrombophlebitis — administer slowly; rotate sites
• GI: Nausea, diarrhoea (less severe than oral formulations)
• Hepatic: Elevated LFTs; cholestatic hepatitis (rare; monitor with prolonged IV courses)
• Electrolyte disturbance: Hypokalaemia (clavulanate potassium), hypernatraemia (amoxicillin sodium) — monitor in renal impairment or prolonged use
• Hypersensitivity: Anaphylaxis — immediate resuscitation equipment must be available

Storage

Store unreconstituted vials below 25°C. Use reconstituted solution immediately. Protect from light. Do not freeze. Incompatible with aminoglycosides — flush IV line before and after each dose.

FAQ

Q1: What does "Tyclav 1.2 IV" mean?
"1.2" refers to 1.2 grams total co-amoxiclav per vial — 1000mg amoxicillin + 200mg clavulanate = 1200mg = 1.2g. This is double the 0.6g vial. The naming is standard globally for IV co-amoxiclav (Augmentin 1.2g IV is the originator). The 1.2g is the standard adult treatment dose; the 0.6g vial is used for moderate infections or as building blocks for specific dosing in renal impairment or paediatrics.

Q2: Is Tyclav 1.2 IV adequate for Pseudomonas infections?
No — co-amoxiclav (amoxicillin/clavulanate) has no reliable activity against Pseudomonas aeruginosa. For suspected Pseudomonal infections (HAP/VAP in ICU, severe burns, immunocompromised patients), piperacillin/tazobactam, ceftazidime, ciprofloxacin, or carbapenem antibiotics are required. Tyclav 1.2 IV covers most community-acquired pathogens and many hospital organisms, but not Pseudomonas or MRSA.

Q3: When can a patient be switched from Tyclav 1.2 IV to oral Tyclav?
IV-to-oral step-down is appropriate when: (1) patient has been afebrile for 24–48 hours with normalising inflammatory markers; (2) can swallow and absorb oral medication; (3) adequate oral bioavailability expected (not severe malabsorption). Switch to Tyclav 1gm BD or 625mg TDS. Step-down reduces treatment cost, avoids IV complications, and allows earlier discharge.

Q4: Can Tyclav 1.2 IV be given as a single pre-operative prophylaxis dose?
Yes — 1.2g IV at anaesthesia induction is a standard antibiotic prophylaxis regimen for many surgical procedures including colorectal, biliary, gynaecological, and orthopaedic surgery. A repeat dose should be given if surgery extends beyond 3 hours or if there is significant blood loss (>1500mL). Post-operative prophylactic dosing beyond 24 hours is generally not recommended.

Medical Disclaimer: Educational information only. IV antibiotics must be prescribed and administered by qualified healthcare professionals. Prescription required. Hospital use only.